Krystal Biotech, Inc. KRYS

KRYS Company Overview

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines using a proprietary redosable herpes simplex virus type 1 (HSV-1) vector platform. The company operates within the biotechnology and gene therapy industries, with a strategic emphasis on dermatology and rare genetic diseases. Its core value proposition is the localized, redosable delivery of gene therapies designed to address the underlying genetic causes of disease rather than symptoms.

The company’s primary revenue driver is its lead product, VYJUVEK, a topical gene therapy approved for dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disorder. Krystal Biotech was founded in 2016 and progressed rapidly from platform development to commercialization, achieving U.S. Food and Drug Administration approval for VYJUVEK in 2023. Since its inception, the company has evolved from a research-focused startup into a vertically integrated gene therapy company with internal manufacturing, commercialization, and clinical development capabilities.